A NEW STABILITY INDICATING UPLC METHOD FOR THE DETERMINATION OF TWO ANTIDIABETIC DRUGS IN COMBINATION: APPLICATIONS TO BULK AND TABLET FORMULATION

A. KRISHNAMANJARI PAWAR; TAREKEGN TADESSE UNADE

doi:10.22159/ijap.2022v14i4.44774

Authors

A. KRISHNAMANJARI PAWAR A. U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530003, Andhra Pradesh, India
TAREKEGN TADESSE UNADE A. U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530003, Andhra Pradesh, India https://orcid.org/0000-0002-7137-6756

DOI:

https://doi.org/10.22159/ijap.2022v14i4.44774

Keywords:

Gliclazide, Metformin, Stability-indicating, UPLC

Abstract

Objective: This work was intended to develop a rapid and sensitive stability-indicating ultra-performance liquid chromatographic (UPLC) method for the determination of Metformin and Gliclazide simultaneously in their pharmaceutical bulk and tablet formulation.

Methods: Separation was performed on Lunna C18 (100 mm x 2.6 mm, 1.6µ) column by using trifluoroacetic acid buffer: acetonitrile (70: 30, v/v) as a mobile phase at a flow rate of 1 ml/min and a wavelength of detection of 227 nm. Method validation and forced degradation studies were conducted per the respective guidelines of the International Conference on Harmonization.

Results: Retention times under the optimized condition were 1.719 min and 2.845 min for Metformin and Gliclazide, respectively. Linearity ranged between 25.0-375.0 µg/ml for Metformin and 4.0-60.0 µg/ml for Gliclazide with a coefficient of determinations (r²) of greater than 0.99. The limit of detection values was 0.25 µg/ml for Metformin and 0.04 µg/ml for Gliclazide. Recovery results ranged from 99.63-101.23 %, and the % RSDs for the precision studies were less than 1.11% for both drugs. The % degradations at various stress conditions ranged from 14.0-5.0% for Metformin and 13.3-2.4% for Gliclazide. The analyte peaks were clearly resolved from the degradant peaks in forced degradation studies.

Conclusion: A fast, sensitive and efficient ultra-performance liquid chromatographic method was successfully developed and validated for the concurrent estimation of Metformin and Gliclazide in their combination, and thus the proposed method can be effectively applied for routine quality control works.

Downloads

Download data is not yet available.

References

International Diabetic Federation. Type 2 diabetes. Available from: https://www.idf.org/aboutdiabetes/type-2-diabetes. [Last accessed on 15 Nov 2021].

Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol. 2017 Jan 24;8(6):6. doi: 10.3389/fendo.2017.00006, PMID 28167928.

Alhadramy MS. Diabetes and oral therapies: a review of oral therapies for diabetes mellitus. J Taibah Univ Med Sci. 2016 Mar 21;11(4):317-29.

Lavernia F, Adkins SE, Shubrook JH. Use of oral combination therapy for type 2 diabetes in primary care: meeting individualized patient goals. Postgrad Med. 2015 Oct 6;127(8):808-17. doi: 10.1080/00325481.2015.1085293, PMID 26439384.

Li J, Lian H. Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus: a comprehensive summary for antidiabetic drugs. Arch Pharm Res. 2016 May 26;39(6):731-46. doi: 10.1007/s12272-016-0762-4, PMID 27230777.

Pareek A, Chandurkar N, Zawar S, Agrawal N. Evaluation of efficacy and tolerability of gliclazide and metformin combination: A multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin. Am J Ther. 2010 Nov-Dec;17(6):559-65. doi: 10.1097/ MJT.0b013e3181c6c0f9, PMID 20093927.

Gottwald Hostalek U. Combination therapy with metformin plus gliclazide in patients with type 2 diabetes. J Dia Res Ther 2020;2(3). doi: 10.16966/2380-5544.119.

Aleti R, Baratam SR, Jagirapu B, Kudamala S. Formulation and evaluation of metformin hydrochloride and gliclazide sustained release bilayer tablets: A combination therapy in management of diabetes. Int J App Pharm. 2021 Sep 07;13(5):343-50. doi: 10.22159/ijap.2021v13i5.41339.

Song R. Mechanism of metformin: a tale of two sites. Diabetes Care. 2016 Feb 01;39(2):187-9. doi: 10.2337/dci15-0013, PMID 26798149.

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017 Aug 03;60(9):1577-85. doi: 10.1007/s00125-017-4342-z, PMID 28776086.

Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs. 1993 Jul;46(1):92-125. doi: 10.2165/00003495-199346010-00007, PMID 7691511.

Sarkar A, Tiwari A, Bhasin PS, Mitra M. Pharmacological and pharmaceutical profile of gliclazide: a review. J Appl Pharm Sci. 2011;1(9):11-9.

Jayapala Reddy K, Krishna Mohan G. Comparative antidiabetic activity of marketed gliclazide formulation with gliclazide loaded pellets containing gum kondagogu as a drug retarding material in rats. Asian J Pharm Clin Res. 2013 Nov 01;6(5):73-5.

Dhabale PN, Seervi CR. Simultaneous UV spectrophotometric method for estimation of gliclazide and metformin hydrochloride in tablet dosage form. Int J ChemTech Res. 2010;2(2):813-7.

Dadhania KP, Nadpara PA, Agrawal YK. Development and validation of a spectrophotometric method for simultaneous estimation of gliclazide and metformin hydrochloride in bulk and tablet dosage form by simultaneous equation method. Int J Pharm Sci Res. 2011 Jun 01;2(6):1559-63. doi: 10.13040/IJPSR.0975-8232.2(6).1559-63.

Fatema K, Rahman MZ, Haque T, Azad MAK, Reza MS. Development and validation of a simple method for simultaneous estimation of metformin hydrochloride and gliclazide in tablets by using reversed phase high performance liquid chromatography. Dhaka Univ J Pharm Sci. 2010;9(2):83-9. doi: 10.3329/dujps.v9i2.7884.

Goud ESK, Reddy VK, Sekhar CK. A new simple RP–HPLC method for simultaneous estimation of metformin HCl and gliclazide tablet dosage form. Int J Pharm Biol Sci. 2012;2(4):277-83.

Nirupamam D, Venkateswar Rao P, Thangabalan B, Babu SM. Development and validation of RP-HPLC method for simultaneous estimation of gliclazide and metformin in pure and tablet dosage form. Int J Pharm and Anal Res. 2014;3(4):326-33.

Pawar J, Sonawane S, Chhajed S, Kshirsagar S. Development and Validation of RP-HPLC method for simultaneous Estimation of metformin HCl and gliclazide. Asian J Pharm Anal. 2016;6(3):151-4. doi: 10.5958/2231-5675.2016.00024.7.

Gedawy A, Al-Salami H, Dass CR. Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide. J Food Drug Anal. 2019;27(1):315-22. doi: 10.1016/j.jfda.2018.06.007. PMID 30648585.

Al-Bathish MY, Gazy AA, El-Jamal MK. RP-HPLC and chemometric methods for the determination of two anti-diabetic mixtures; metformin hydrochloride-canagliflozin and metformin hydrochloride-gliclazide in their pharmaceutical formulation. Int J Pharm Pharm Sci. 2020 Feb 01;12(2):83-94. doi: 10.22159/ijpps.2020v12i2.35415.

Patil V, Kale S, Sahare P, Vithaldas S. Simultaneous HPTLC analysis of gliclazide and metformin hydrochloride in bulk and tablet dosage form. J Sci Innov Res. 2014;3(3):325-31. doi: 10.31254/jsir.2014.3309.

Ranetti M, Ionescu M, Hinescu L, Ionică E, Anuţa V, Ranetti AE et al. Validation of a HPLC method for the simultaneous analysis of metformin and gliclazide in human plasma. Farmacia. 2009;57(6):728-35.

Meenakshi D, Meenaxi M. A review on ultraperformance liquid chromatography. Int. Drug Dev. 2013;5(2):29-34.

Nahar L, Onder A, Sarker SD. A review on the recent advances in HPLC, UHPLC and UPLC analyses of naturally occurring cannabinoids (2010-2019). Phytochem Anal. 2020 Jul;31(4):413-57. doi: 10.1002/pca.2906, PMID 31849137.

International Conference on Harmonization. ICH Harmonized tripartite guideline. Validation of Analytical Procedures: Text and Methodology. Vol. Q2. Geneva, Switzerland; 2005. p. R1.

International Conference on Harmonization. ICH Harmonized tripartite guideline. Stability Testing of New Drug Substances and Products. Vol. Q1A. Geneva, Switzerland; 2003. p. R2.

Gurrala S, Raj S, Cvs S, Anumolu PD. Quality-by-design approach for chromatographic analysis of metformin, empagliflozin and linagliptin. J Chromatogr Sci. 2022;60(1):68-80. doi: 10.1093/chromsci/bmab030. PMID 33822920.